NCT06605950View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

KarXT

Specified dose on specified days

DRUG

KarX-EC

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

DRUG

Omeprazole

Specified dose on specified days

Trial Locations (1)

92801

Cenexel ACT (Anaheim Clinical Trials), Anaheim

Sponsors
All Listed Sponsors
lead

Karuna Therapeutics

INDUSTRY

NCT06605950 - A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants | Biotech Hunter | Biotech Hunter